QuidelOrtho Corporation (QDEL)
QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript
QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
QuidelOrtho (QDEL) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago.
Earnings Preview: QuidelOrtho (QDEL) Q4 Earnings Expected to Decline
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL's decent Q3 2025 results and expanding diagnostics portfolio support near-term growth despite respiratory reliance and payer risks.
QuidelOrtho Corporation (QDEL) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
QuidelOrtho Corporation (QDEL) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
QuidelOrtho Q3 Earnings and Revenues Beat Estimates, Margins Expand
QDEL tops Q3 estimates as Labs and Immunohematology units drive growth, while margins strengthen despite respiratory revenue declines.
QuidelOrtho Corporation (QDEL) Q3 2025 Earnings Call Transcript
QuidelOrtho Corporation ( QDEL ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Juliet Cunningham - Vice President of Investor Relations Brian Blaser - President, CEO & Director Joseph Busky - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair & Company L.L.C., Research Division Lu Li - UBS Investment Bank, Research Division Jack Meehan - Nephron Research LLC Jack Melick - Jefferies LLC, Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Presentation Operator Welcome to the QuidelOrtho Third Quarter 2025 Financial Results Conference Call and webcast.
QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test
QDEL boosts its respiratory testing lineup with the FDA-cleared QUICKVUE Influenza + SARS Test for professional use.
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Value Investors Buy QuidelOrtho (QDEL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
QuidelOrtho Stock Gains Following Q2 Earnings Beat, Margins Expand
QDEL stock rises 12.8% after Q2 earnings beat. Adjusted margins improve amid soft revenue and ongoing business headwinds.
QuidelOrtho Corporation (QDEL) Q2 2025 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Brian J. Blaser - President, CEO & Director Joseph M.
